AstraZeneca reports disappointing final stage trials of diabetes drug in COVID-19 treatment
The primary goals were prevention of organ dysfunction and death as well as recovery over 30 days
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 23 of 55
UK has enough COVID-19 vaccines for under 30s after decision on AstraZeneca jab, says minister
Also, a new study suggests there is a correlation between the fall in deaths and the vaccine rollout in the UK
Are AstraZeneca shares still a 'buy'? These two heavyweight banks think so
Both UBS and Citi restated their guidance on the stock
AstraZeneca COVID-19 jab developer Vaccitech prepares for £509mln New York IPO
One of the co-founders is Sarah Gilbert, the University of Oxford professor behind the vaccine
AstraZeneca vaccine should not be offered to healthy under 30s, UK government says
The authorities stressed that the jab's benefits continue to outweigh the risks
AstraZeneca COVID-19 vaccine fine for use, says EU regulator
The benefits in preventing the disease outweigh risks of side effects, the EMA said
Moderna vaccine introduced weeks early as verdict on AstraZeneca jab awaited
The shot is expected to be used in the rest of the United Kingdom by the middle of April.
Valneva gives UK vaccine progamme another boost with strong trial result
Valneva's vaccine VLA2001 also sparked broad T-cell responses
AstraZeneca vaccine might be restricted to over-30s due to blood clot concern
“No decision has yet been made on any regulatory action.”
Archive
FTSE 100 ends higher on lockdown easing hopes; Wall Street mixed after initial false start
The UK blue chip index remained buoyant but Wall Street sees some profit taking after this week's new records
Archive
Today's Market View - Condor Gold; Conroy Gold & Natural Resources; IronRidge Resources; Vast Resources and more...
Condor Gold* (AIM:CNR) 47.5p, Mkt Cap £62.0m – Progress of infill drilling at La India Condor Gold reports that it has now completed the first 40 holes (2,170m) of its closely spaced infill drilling programme within the area of the starter
UK to share COVID-19 surplus vaccines abroad after all adults vaccinated
Business minister Kwasi Kwarteng said the “focus has to be to try and keep Britain safe” as over 30mln people have received a jab
AstraZeneca urged to catch up with COVID-19 vaccine deliveries by EU chief
Meanwhile, the University of Oxford is launching a study to deliver the vaccine via a nasal spray instead of injecting it
AstraZeneca publishes primary COVID-19 vaccine trial results consistent with Monday data
The primary analysis will be the basis for a regulatory submission for Emergency Use Authorization in the US
Archive
Today's Market View - Altus Strategies; Oriole Resources and more...
Altus Strategies* (AIM:ALS) - BUY – Drilling intersects potential new parallel gold zone at Tabakorole Oriole Resources (LON:ORR) – Senala exploration plan Rio Tinto (LON:RIO) – Rio Tinto’s plan to strengthen “Cultural Heritage management”
US agency asks AstraZeneca to review COVID-19 vaccine trial results
It is understood that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data
Coronavirus: Boris Johnson to lobby EU leaders to halt AstraZeneca vaccine export ban
The Commission is looking to prevent jabs made on the continent to be delivered abroad because AstraZeneca is not meeting contractual obligations
AstraZeneca says COVID-19 vaccine shows 100% efficacy against severe disease, hospitalisation with no safety concerns
An independent committee found no increased risk of thrombosis in late-stage trials of over 32,000 people
AstraZeneca to hear from EU regulator on COVID-19 vaccine today
Experts from the European Medicines Agency are discussing whether to keep rolling out the jab in the bloc
AstraZeneca upgraded to ‘buy’ by Jefferies as pipeline should aid recovery of shares
The US investment bank reckons the risk-reward is significantly more positive